AXT and CELLINK Form a Formidable Australian Bioprinting Partnership

3D bioprinting is experiencing rapid growth as the technology continues to evolve. Academic researchers and commercial organizations employ the technology for a range of applications including tissue engineering, regenerative medicine, drug discovery, personalized medicine and more. This is certainly the case in Australia and AXT, who are already well entrenched in the field are pleased to announce that they are strengthening their position by partnering with CELLINK.

Image credit: AXT/CELLINK

CELLINK are leaders in 3D bioprinting with a range of light and extrusion-based bioprinters. Today CELLINK boasts over 1600 installations (including several in Australia) in over 60 countries and are featured in more than 1200 publications. Their portfolio of bioprinters is supported by a range of bioinks that allow researchers to push the limits of medical research.

CELLINK’s product lineup is headlined by the BIONOVA X, a high-throughput system powered by Digital Light Processing (DLP) technology that allows the printing of high-resolution complex structures at high-speed. The LUMEN X DLP bioprinter offers users precision and versatility. For researchers looking for extrusion-based bioprinters, the modular BIO X series allow simultaneous printing using up to six bioinks. The popular INKREDIBLE extrusion bioprinters round out their range at a cost-effective price point.

Richard Trett, AXT’s Managing Director commented, “Australia has a vibrant growing biomedical research community and bioprinting is a key enabling technology moving rapidly from theoretical research to applied solutions. We already have leading technologies in single cell and biomaterials printing, partnering with CELLINK to extend our bioprinting offering made so much commercial sense that we jumped at the opportunity to work with them”.

Tomoko Bylund, Head of Sales - APAC went further to say, “We are experiencing rapid growth in bioprinting adoption around the world. We could not adequately support the Australian market from abroad and it made sense for us to partner with local-based AXT who are already well established in the field.”

With the addition of CELLINK’s bioprinters to their portfolio, AXT are now the premier supplier of bioprinters in Australia and New Zealand. For more details about AXT’s bioprinting portfolio, including new CELLINK product lines, please visit


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    AXT Pty Ltd. (2023, July 25). AXT and CELLINK Form a Formidable Australian Bioprinting Partnership. News-Medical. Retrieved on July 14, 2024 from

  • MLA

    AXT Pty Ltd. "AXT and CELLINK Form a Formidable Australian Bioprinting Partnership". News-Medical. 14 July 2024. <>.

  • Chicago

    AXT Pty Ltd. "AXT and CELLINK Form a Formidable Australian Bioprinting Partnership". News-Medical. (accessed July 14, 2024).

  • Harvard

    AXT Pty Ltd. 2023. AXT and CELLINK Form a Formidable Australian Bioprinting Partnership. News-Medical, viewed 14 July 2024,


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
AXT add Vieworks bio-imaging solutions to their preclinical imaging portfolio